PT3199180T - Anticorpos epha3 para o tratamento de tumores sólidos - Google Patents
Anticorpos epha3 para o tratamento de tumores sólidosInfo
- Publication number
- PT3199180T PT3199180T PT171597149T PT17159714T PT3199180T PT 3199180 T PT3199180 T PT 3199180T PT 171597149 T PT171597149 T PT 171597149T PT 17159714 T PT17159714 T PT 17159714T PT 3199180 T PT3199180 T PT 3199180T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- solid tumors
- epha3 antibodies
- epha3
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89384807P | 2007-03-08 | 2007-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3199180T true PT3199180T (pt) | 2022-04-01 |
Family
ID=39689392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT171597149T PT3199180T (pt) | 2007-03-08 | 2008-03-10 | Anticorpos epha3 para o tratamento de tumores sólidos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8637016B2 (enExample) |
| EP (2) | EP2136838B1 (enExample) |
| JP (1) | JP5311060B2 (enExample) |
| CN (1) | CN101641115B (enExample) |
| AU (1) | AU2008226905C1 (enExample) |
| CA (1) | CA2679986C (enExample) |
| DK (1) | DK3199180T3 (enExample) |
| ES (1) | ES2910298T3 (enExample) |
| IL (1) | IL200764A (enExample) |
| NZ (1) | NZ579478A (enExample) |
| PL (1) | PL3199180T3 (enExample) |
| PT (1) | PT3199180T (enExample) |
| WO (1) | WO2008112192A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2222846B1 (en) | 2007-08-10 | 2017-05-03 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| WO2010102244A1 (en) * | 2009-03-06 | 2010-09-10 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
| PT2488554T (pt) | 2009-10-14 | 2019-09-13 | Humanigen Inc | Anticorpos para epha3 |
| US20110243934A1 (en) * | 2010-04-01 | 2011-10-06 | Kalobios Pharmaceuticals Inc. | Epha3 antibodies for the treatment of multiple myeloma |
| EP2582388A4 (en) * | 2010-06-18 | 2014-04-16 | Kalobios Pharmaceuticals Inc | IDENTIFYING EPHA3 AS A MARKER FOR THE PRESENCE OF A SOLID TUMOR |
| MX356400B (es) * | 2010-12-08 | 2018-05-28 | Abbvie Stemcentrx Llc | Moduladores novedosos y metodos de uso. |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US9109032B2 (en) | 2011-08-12 | 2015-08-18 | Kalobios Pharmaceuticals, Inc. | Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow |
| PL3068797T3 (pl) * | 2013-11-11 | 2020-06-29 | Wake Forest University Health Sciences | Konstrukty wielowalentnego celowania w nowotwory |
| CN109476756B (zh) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| CN114787190A (zh) * | 2019-10-09 | 2022-07-22 | 昆士兰医学研究所理事会 | 靶向epha3及其用途 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4997913A (en) * | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| EP0590030B1 (en) | 1991-06-21 | 2004-09-29 | The Walter and Eliza Hall Institute of Medical Research | A receptor-type tyrosine kinase [human eph/elk-like kinase - hek] and use thereof |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| NO175798C (no) | 1992-07-22 | 1994-12-07 | Sinvent As | Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1508337A3 (en) | 1998-11-20 | 2006-04-19 | Genentech, Inc. | Uses for eph receptor antagonists and agonists to treat vascular disorders |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000060070A1 (en) | 1999-04-01 | 2000-10-12 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP1094110A1 (en) | 1999-10-21 | 2001-04-25 | Leadd B.V. | Apoptosis inducing proteinaceous substance |
| AU2001276842B2 (en) | 2000-06-28 | 2007-04-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7041302B2 (en) * | 2001-01-09 | 2006-05-09 | Biother Corporation | Therapeutic modulation of the tumor inflammatory response |
| US6652853B2 (en) * | 2001-03-08 | 2003-11-25 | Ludwig Institute For Cancer Research | Method for treating cancer using A33 specific antibodies and chemotherapeutic agents |
| CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20050049194A1 (en) | 2001-11-09 | 2005-03-03 | Jonas Frisen | Use of ephrins and related molecules to regulate cellular proliferation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CA2799805C (en) | 2002-03-19 | 2016-05-17 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
| WO2003102144A2 (en) | 2002-05-29 | 2003-12-11 | Curagen Corporation | Compositions and methods of use for an ephrin rreceptor |
| EP1553963A4 (en) | 2002-09-24 | 2006-05-03 | Burnham Inst | NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| AU2003900541A0 (en) | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| US20050008649A1 (en) | 2003-06-02 | 2005-01-13 | University Of Miami | Chimeric molecules and methods of use |
| EP2990053A1 (en) | 2004-01-20 | 2016-03-02 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| WO2006023420A2 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| US8222253B2 (en) | 2004-10-23 | 2012-07-17 | Case Western Reserve University | Peptide and small molecule agonists of EphA and their uses |
| EP2422811A2 (en) * | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| PL2343380T3 (pl) | 2004-11-16 | 2020-03-31 | Humanigen, Inc. | Wymiana kasety dla regionu zmiennego immunoglobuliny |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
-
2008
- 2008-03-10 US US12/045,589 patent/US8637016B2/en not_active Expired - Fee Related
- 2008-03-10 ES ES17159714T patent/ES2910298T3/es active Active
- 2008-03-10 PL PL17159714.9T patent/PL3199180T3/pl unknown
- 2008-03-10 CN CN2008800076268A patent/CN101641115B/zh active Active
- 2008-03-10 PT PT171597149T patent/PT3199180T/pt unknown
- 2008-03-10 CA CA2679986A patent/CA2679986C/en active Active
- 2008-03-10 EP EP08726647.4A patent/EP2136838B1/en active Active
- 2008-03-10 DK DK17159714.9T patent/DK3199180T3/da active
- 2008-03-10 WO PCT/US2008/003149 patent/WO2008112192A2/en not_active Ceased
- 2008-03-10 EP EP17159714.9A patent/EP3199180B1/en active Active
- 2008-03-10 NZ NZ579478A patent/NZ579478A/xx not_active IP Right Cessation
- 2008-03-10 JP JP2009552761A patent/JP5311060B2/ja active Active
- 2008-03-10 AU AU2008226905A patent/AU2008226905C1/en active Active
-
2009
- 2009-09-06 IL IL200764A patent/IL200764A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008226905C1 (en) | 2014-11-06 |
| US20080286272A1 (en) | 2008-11-20 |
| IL200764A (en) | 2017-01-31 |
| IL200764A0 (en) | 2010-05-17 |
| CN101641115B (zh) | 2013-04-24 |
| CN101641115A (zh) | 2010-02-03 |
| EP3199180B1 (en) | 2022-01-05 |
| NZ579478A (en) | 2012-08-31 |
| ES2910298T3 (es) | 2022-05-12 |
| AU2008226905A1 (en) | 2008-09-18 |
| EP2136838B1 (en) | 2017-03-08 |
| EP3199180A1 (en) | 2017-08-02 |
| WO2008112192A2 (en) | 2008-09-18 |
| JP5311060B2 (ja) | 2013-10-09 |
| JP2010520290A (ja) | 2010-06-10 |
| PL3199180T3 (pl) | 2022-08-08 |
| CA2679986C (en) | 2018-03-06 |
| DK3199180T3 (da) | 2022-03-21 |
| CA2679986A1 (en) | 2008-09-18 |
| AU2008226905B2 (en) | 2014-05-01 |
| EP2136838A2 (en) | 2009-12-30 |
| WO2008112192A3 (en) | 2008-11-13 |
| US8637016B2 (en) | 2014-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2000048I1 (hu) | Új anti-CD38 ellenanyagok, rák kezelésére | |
| PL3199180T3 (pl) | Przeciwciała przeciwko epha3 do leczenia guzów litych | |
| ZA200900545B (en) | Antagonist antibody against EPHA2 for the treatment of cancer | |
| PL2303021T3 (pl) | Związki do leczenia nowotworu | |
| IL191832A0 (en) | Pyridiazinone derivatives for the treatment of tumours | |
| ZA200905012B (en) | Process for the preparation of certain substituted sulfimines | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| IL201245A0 (en) | An improved process for the synthesis of solifenacin | |
| ZA200907191B (en) | Process for the preparation of gefitiib | |
| ZA200804264B (en) | Process for the preparation of ferri-succinylcasein | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| ZA200601910B (en) | Process for the preparation of organosilances | |
| ZA201001546B (en) | Isoxazole compounds for the treatment of cancer | |
| IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| GB0517387D0 (en) | Combinations for the treatment of cancer | |
| IL226362A0 (en) | compounds, and methods for treating cancer | |
| GB2459413B (en) | Methods for the synthesis of perfluoroparacyclophane | |
| ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
| ZA200706871B (en) | Treatment of metastasized tumors | |
| IL205339A0 (en) | Compounds and methods for the treatment of cancer | |
| GB0517386D0 (en) | Combinations for the treatment of cancer | |
| GB0604114D0 (en) | Combinations for the treatment of cancer | |
| AU2007907021A0 (en) | Antibodies for the treatment of periodontal disease | |
| AU2007901333A0 (en) | Method for the treatment of cancer | |
| HK1139060A (en) | Raf inhibitors for the treatment of thyroid cancer |